ImmuPharma (LON:IMM) Trading 27.3% Higher - What's Next?

Key Points

• ImmuPharma plc's shares rose by 27.3% on Friday, reaching as high as GBX 12.75 ($0.17), following a previous close at GBX 9.90 ($0.13).
• The company's market cap is approximately £63.34 million with a current price-to-earnings ratio of -1,415.73 and expected EPS of -339.0000022 for the fiscal year.
• ImmuPharma specializes in developing peptide-based therapeutics for autoimmune diseases, with its lead program, Lupuzor™, targeting Lupus treatment.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) traded up 27.3% during mid-day trading on Friday . The company traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). 4,543,810 shares were traded during trading, a decline of 46% from the average session volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Trading Up 27.3%

The stock has a 50-day simple moving average of GBX 7.92 and a 200-day simple moving average of GBX 4.36. The company has a market cap of £63.34 million, a price-to-earnings ratio of -1,415.73 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, research analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.